0	1	{'start':(0, 0), 'end':(0, 6), 'text':'Immunoglobulin E Receptor Signaling and Asthma *'}
6	27	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'Introduction'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 3), 'text':'Asthma is a disease'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 4), 'end':(1, 16), 'text':'characterized by reversible airway obstruction , airway hyper-reactivity , and chronic airway inflammation'}, {'start':(1, 17), 'end':(1, 34), 'text':'that manifest as symptoms such as coughing , shortness of breath , chest tightness , and wheezing .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(2, 0), 'end':(2, 11), 'text':'Asthma is estimated to affect up to 300 million people worldwide ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 12), 'end':(2, 28), 'text':'and although the majority of asthmatics are well controlled by treatment with inhaled corticosteroids and bronchodilators ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 29), 'end':(2, 43), 'text':'many asthmatics are still inadequately controlled by current therapies , with the most severe asthmatics'}, {'start':(2, 44), 'end':(2, 52), 'text':'responding poorly to all available medications ( ) .'}]}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 20), 'text':'Given that the most severe 5-10 % of asthmatics are estimated to account for nearly 50 % of total healthcare costs'}, {'start':(3, 21), 'end':(3, 24), 'text':'related to asthma ,'}]}, {'start':(3, 25), 'end':(3, 40), 'text':'there is a significant need for new therapies for the treatment of asthma ( ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 6), 'text':'Asthma is one of several allergic diseases'}, {'start':(4, 7), 'end':(4, 20), 'text':'that are associated with elevated IgE levels and increased IgE sensitization to allergens .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(5, 0), 'end':(5, 24), 'text':'IgE binds to two different receptors , the high-affinity Fcepsilon receptor I ( FcepsilonRI ) and the low-affinity receptor FcepsilonRII and CD23 ( ) .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 11), 'text':'In humans , FcepsilonRI is found on mast cells and basophils ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 12), 'end':(6, 17), 'text':'where it is a tetrameric complex'}, {'start':(6, 18), 'end':(6, 31), 'text':'consisting of one alpha-chain , one beta-chain , and two disulfide bonded gamma-chains ,'}]}]}, {'start':(6, 32), 'end':(6, 44), 'text':'and on dendritic cells , Langerhans cells , macrophages , and eosinophils ,'}]}, {'start':(6, 45), 'end':(6, 50), 'text':'where it is a trimeric complex'}]}, {'start':(6, 51), 'end':(6, 54), 'text':'consisting of one alpha-chain'}]}, {'start':(6, 55), 'end':(6, 62), 'text':'and two disulfide bonded gamma-chains ( ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'explanation', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 10), 'text':'The FcepsilonRI alpha-subunit ( FcepsilonRIalpha ) is unique to FcepsilonRI ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 11), 'end':(7, 36), 'text':'whereas the beta- and gamma-subunits ( FcRbeta and FcRgamma , respectively ) form complexes with other Fc receptors and , in the case of FcRgamma ,'}, {'start':(7, 37), 'end':(7, 46), 'text':'the T cell receptor , in addition to FcepsilonRI .'}]}]}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 7), 'text':'IgE stabilizes the cell surface levels of FcepsilonRI'}, {'start':(8, 8), 'end':(8, 21), 'text':'by preventing the internalization of the receptor from the cell surface ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(9, 0), 'end':(9, 10), 'text':'The up regulation of cell surface FcepsilonRI levels by IgE increases'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 11), 'end':(9, 17), 'text':'the sensitivity of cells to FcepsilonRI activation'}, {'start':(9, 18), 'end':(9, 22), 'text':'triggered by allergen induced cross'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 23), 'end':(9, 25), 'text':'linking of IgE'}, {'start':(9, 26), 'end':(9, 31), 'text':'that is bound to FcepsilonRI .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 18), 'text':'Activation of FcepsilonRI on mast cells and basophils leads to degranulation , eicosanoid production , and cytokine production ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 19), 'end':(10, 27), 'text':'which are associated with early- and late-phase anaphylactic reactions'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 28), 'end':(10, 34), 'text':'that can result in exacerbations of asthma'}, {'start':(10, 35), 'end':(10, 38), 'text':'( - ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 16), 'text':'Activation of FcepsilonRI on dendritic cells leads to increased antigen presentation and cytokine and chemokine production ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 17), 'end':(11, 24), 'text':'which may enhance T-helper 2 cell sensitization ,'}, {'start':(11, 25), 'end':(11, 37), 'text':'which promotes the allergic inflammation that drives asthma pathogenesis ( - ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 0), 'end':(12, 9), 'text':'CD23 is found on B cells and myeloid cells ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 10), 'end':(12, 15), 'text':'where it is a homotrimeric complex'}, {'label':'joint', 'direction':'None', 'children':[{'start':(12, 16), 'end':(12, 19), 'text':'that regulates IgE synthesis'}, {'start':(12, 20), 'end':(12, 24), 'text':'and mediates antigen presentation .'}]}]}]}]}, {'label':'contrast', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 27), 'text':'A key role for FcepsilonRI signaling in the pathogenesis of allergic asthma was demonstrated by the therapeutic neutralization of serum IgE in moderate and severe allergic asthmatics ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 28), 'end':(13, 29), 'text':'including those'}, {'start':(13, 30), 'end':(13, 37), 'text':'who respond poorly to all other therapies ,'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 38), 'end':(13, 41), 'text':'using a monoclonal antibody'}, {'start':(13, 42), 'end':(13, 53), 'text':'that blocks the binding of IgE to both of its receptors .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 8), 'text':'Treatment with anti-IgE antibody results in significant anti-inflammatory effects'}, {'start':(14, 9), 'end':(14, 23), 'text':'that ultimately lead to a reduction in the frequency of asthma exacerbations ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 24), 'text':'Upon neutralization of serum IgE , cell surface FcepsilonRI levels are reduced on mast cells , basophils , and dendritic cells ( - ) .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(16, 0), 'end':(16, 14), 'text':'The reduction in mast cell and basophil surface FcepsilonRI levels results in decreased FcepsilonRI activation'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 15), 'end':(16, 22), 'text':'and is proposed to be the primary mechanism'}, {'start':(16, 23), 'end':(16, 29), 'text':'underlying the efficacy of anti-IgE treatment .'}]}]}]}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 0), 'end':(17, 10), 'text':'However , anti-IgE therapy does not completely abrogate FcepsilonRI activation ;'}, {'start':(17, 11), 'end':(17, 25), 'text':'has a relatively slow onset of efficacy ; and , due to dosing limitations ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 26), 'end':(17, 36), 'text':'is not approved for patients with very high IgE levels ,'}, {'start':(17, 37), 'end':(17, 47), 'text':'who might benefit the most from neutralization of serum IgE .'}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(18, 0), 'end':(18, 11), 'text':'Thus , approaches that inhibit FcepsilonRI activation more directly , potently ,'}, {'start':(18, 12), 'end':(18, 26), 'text':'and quickly than anti-IgE therapy are promising new therapies for the treatment of asthma .'}]}, {'start':(19, 0), 'end':(19, 36), 'text':'Given the important role of FcepsilonRI signaling and mast cell activation in asthma pathogenesis , this minireview focuses on recent advances in our understanding of the positive and negative regulation of FcepsilonRI signaling in mast cells .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 10), 'text':'For a detailed discussion of CD23 , see several excellent reviews'}, {'start':(20, 11), 'end':(20, 20), 'text':'that cover CD23 structure , signaling , and function .'}]}]}
109	122	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 4), 'text':'Calcium Signaling Downstream of FcepsilonRI'}, {'start':(1, 0), 'end':(1, 17), 'text':'Intracellular calcium signaling contributes to degranulation , eicosanoid production , and cytokine production downstream of FcepsilonRI activation .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(2, 0), 'end':(2, 24), 'text':'FcepsilonRI induced calcium signaling in mast cells occurs in two steps , the first being release of calcium from intracellular calcium stores in the ER'}, {'start':(2, 25), 'end':(2, 42), 'text':'and the second being calcium influx from the extracellular space through store operated calcium channels ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 7), 'text':'Intracellular calcium signaling is regulated by PLCgamma ,'}, {'start':(3, 8), 'end':(3, 17), 'text':'which generates inositol 1,4,5-trisphosphate and diacylglycerol from PIP 2 .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 17), 'text':'Inositol 1,4,5-trisphosphate stimulates the release of intracellular calcium stores upon binding to its receptor in the ER .'}, {'start':(5, 0), 'end':(5, 11), 'text':'The depletion of ER calcium stores then triggers extracellular calcium influx .'}]}, {'label':'cause', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 9), 'text':'Diacylglycerol and intracellular calcium signals cooperate to activate PKCs ,'}, {'start':(6, 10), 'end':(6, 20), 'text':'which then activate other pathways such as the NF-kappaB pathway ,'}]}, {'start':(6, 21), 'end':(6, 30), 'text':'ultimately leading to mast cell degranulation and cytokine production .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(7, 0), 'end':(7, 21), 'text':'Our understanding of intracellular calcium signaling has advanced significantly in recent years due to the discovery of the identity of key components'}, {'start':(7, 22), 'end':(7, 29), 'text':'and regulators of store operated calcium channels .'}]}]}]}, {'label':'explanation', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(8, 0), 'end':(8, 6), 'text':'STIM1 ( stromal interaction molecule 1 )'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(8, 7), 'end':(8, 8), 'text':'was identified'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 9), 'end':(8, 16), 'text':'as a calcium sensor located in the ER'}, {'start':(8, 17), 'end':(8, 34), 'text':'that couples the depletion of intracellular ER calcium stores to the activation of store operated calcium channels .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 8), 'text':'Orai1 and CRACM1 is a recently discovered membrane protein'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 9), 'end':(9, 15), 'text':'that constitutes the store operated calcium channel'}, {'start':(9, 16), 'end':(9, 19), 'text':'( - ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 9), 'text':'Mutation of Orai1 in humans results in severe combined immunodeficiency'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 10), 'end':(10, 17), 'text':'that is due to a lack of store'}, {'start':(10, 18), 'end':(10, 22), 'text':'operated calcium channel function .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 27), 'text':'Both STIM1 and Orai1 knock-out mast cells are deficient in intracellular calcium signaling downstream of FcepsilonRI activation due to defective influx of calcium from the extracellular space ,'}, {'start':(11, 28), 'end':(11, 41), 'text':'leading to defective mast cell degranulation , eicosanoid production , and cytokine production .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(12, 0), 'end':(12, 2), 'text':'Recent data indicate'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 3), 'end':(12, 11), 'text':'that Syk is a local sensor of calcium signaling'}, {'start':(12, 12), 'end':(12, 21), 'text':'that contributes to a positive feedback loop downstream of store'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 22), 'end':(12, 29), 'text':'operated calcium channel opening and that also couples'}, {'start':(12, 30), 'end':(12, 41), 'text':'extracellular calcium influx to the activation of PKC and other pathways .'}]}]}]}]}]}]}
1	6	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 15), 'text':'Elevated IgE levels and increased IgE sensitization to allergens are central features of allergic asthma .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(1, 0), 'end':(1, 19), 'text':'IgE binds to the high-affinity Fcepsilon receptor I ( FcepsilonRI ) on mast cells , basophils , and dendritic cells'}, {'start':(1, 20), 'end':(1, 21), 'text':'and mediates'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 22), 'end':(1, 28), 'text':'the activation of these cells upon antigen'}, {'start':(1, 29), 'end':(1, 30), 'text':'induced cross'}]}, {'start':(1, 31), 'end':(1, 36), 'text':'linking of IgE bound FcepsilonRI .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 5), 'text':'FcepsilonRI activation proceeds through a network'}, {'label':'joint', 'direction':'None', 'children':[{'start':(2, 6), 'end':(2, 11), 'text':'of signaling molecules and adaptor proteins'}, {'start':(2, 12), 'end':(2, 25), 'text':'and is negatively regulated by a number of cell surface and intracellular proteins .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 22), 'text':'Therapeutic neutralization of serum IgE in moderate-to-severe allergic asthmatics reduces the frequency of asthma exacerbations through a reduction in cell surface FcepsilonRI expression'}, {'start':(3, 23), 'end':(3, 29), 'text':'that results in decreased FcepsilonRI activation ,'}]}, {'start':(3, 30), 'end':(3, 35), 'text':'leading to improved asthma control .'}]}, {'start':(4, 0), 'end':(4, 20), 'text':'Our increasing understanding of IgE receptor signaling may lead to the development of novel therapeutics for the treatment of asthma .'}]}]}
72	82	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 4), 'text':'Adaptor Proteins in FcepsilonRI Signaling'}, {'start':(1, 0), 'end':(1, 14), 'text':'Two major adaptor proteins downstream of FcepsilonRI signaling are LAT and NTAL/LAB/LAT2 ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 13), 'text':'Phosphorylation of LAT by Syk leads to the recruitment and activation of phospholipase Cgamma'}, {'start':(2, 14), 'end':(2, 17), 'text':'( PLCgamma ) ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 18), 'end':(2, 37), 'text':'which is discussed further below , as well as the recruitment and activation of Ras and Rho GTPases and MAPKs'}, {'start':(2, 38), 'end':(2, 47), 'text':'( i.e. p38 , JNK , and ERK ) ,'}]}]}, {'start':(2, 48), 'end':(2, 62), 'text':'leading to mast cell degranulation , eicosanoid production , and cytokine production ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 17), 'text':'The LAT adaptor protein integrates both positive and negative regulatory signals downstream of FcepsilonRI activation ( ) ,'}, {'start':(3, 18), 'end':(3, 28), 'text':'leading to an overall positive regulatory role in FcepsilonRI signaling .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 14), 'text':'The overall role of NTAL in FcepsilonRI signaling is less clear , with different studies'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 15), 'end':(4, 21), 'text':'indicating either positive or negative regulatory roles'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 22), 'end':(4, 31), 'text':'based on mouse gene knock-out and human RNAi knockdown studies'}, {'start':(4, 32), 'end':(4, 43), 'text':'in which the entire NTAL protein was deleted ( - ) .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 20), 'text':'Two recent studies have focused on a positive regulatory role for NTAL in linking FcepsilonRI activation to PLCgamma activation through pathways'}, {'start':(5, 21), 'end':(5, 24), 'text':'that are parallel to'}]}, {'start':(5, 25), 'end':(5, 32), 'text':'and independent of LAT mediated PLCgamma activation .'}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(6, 0), 'end':(6, 2), 'text':'One study demonstrated'}, {'start':(6, 3), 'end':(6, 13), 'text':'that the adaptor protein Grb2 is recruited to phosphorylated NTAL .'}]}]}, {'start':(7, 0), 'end':(7, 14), 'text':'The subsequent phosphorylation of Grb2 triggers the recruitment and activation of PLCgamma ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(8, 0), 'end':(8, 3), 'text':'The other study showed'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 4), 'end':(8, 10), 'text':'that a Gads- and SLP76 mediated pathway'}, {'start':(8, 11), 'end':(8, 24), 'text':'that is coupled to NTAL links FcepsilonRI activation to PLCgamma activation ( ) .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 11), 'text':'Aside from LAT and NTAL , a number of additional adaptor proteins'}, {'start':(9, 12), 'end':(9, 19), 'text':'that play a role in FcepsilonRI signaling ,'}]}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(9, 20), 'end':(9, 27), 'text':'many of which associate with LAT and NTAL'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 28), 'end':(9, 32), 'text':'to form large scaffolding complexes'}, {'start':(9, 33), 'end':(9, 42), 'text':'( e.g. Grb2 , Gads , and SLP76 ) ,'}]}]}]}, {'start':(9, 43), 'end':(9, 51), 'text':'have been extensively discussed by others ( ) .'}]}]}]}]}]}
122	138	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 4), 'text':'Negative Regulators of FcepsilonRI Signaling'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 13), 'text':'Negative regulators of FcepsilonRI signaling can be grouped into intracellular and cell surface proteins'}, {'start':(1, 14), 'end':(1, 26), 'text':'that act at various points in the FcepsilonRI signaling network ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 12), 'text':'Intracellular negative regulators of FcepsilonRI signaling include the SHP-1 and SHP-2 phosphatases ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 13), 'end':(2, 19), 'text':'which inhibit the activity of signaling proteins'}, {'start':(2, 20), 'end':(2, 38), 'text':'that are proximal to FcepsilonRI such as Syk and Fyn and adaptor proteins such as LAT and NTAL .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 5), 'text':'Protein-tyrosine phosphatase epsilon is a phosphatase'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(3, 6), 'end':(3, 17), 'text':'that also acts at a proximal point in the FcepsilonRI signaling network'}, {'start':(3, 18), 'end':(3, 24), 'text':'by inhibiting Syk activity ( ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 12), 'text':'The PI3K pathway is negatively regulated by SHIP and PTEN ( ) ,'}, {'start':(4, 13), 'end':(4, 22), 'text':'which directly dephosphorylate PIP 3 to generate PIP 2 .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 15), 'text':'SHIP dephosphorylates the phosphate at the D5 position of the inositol ring of PIP 3 ,'}, {'start':(5, 16), 'end':(5, 25), 'text':'whereas PTEN dephosphorylates the phosphate at the D3 position .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 11), 'text':'The PI3K pathway is also negatively regulated by RGS13 and LAX ,'}, {'start':(6, 12), 'end':(6, 27), 'text':'which inhibit the interaction of the PI3K p85 regulatory subunit with the Grb2-NTAL scaffolding complex .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 1), 'text':'Mast cells'}, {'start':(7, 2), 'end':(7, 21), 'text':'that are deficient in these negative regulators have heightened degranulation and and or cytokine responses downstream of FcepsilonRI activation .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'explanation', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 5), 'text':'Cell surface proteins on mast cells'}, {'start':(8, 6), 'end':(8, 10), 'text':'that negatively regulate FcepsilonRI activation'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 11), 'end':(8, 12), 'text':'include TRPM4'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 13), 'end':(8, 15), 'text':'( ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 16), 'end':(8, 26), 'text':'which modulates extracellular calcium influx , and TLR4 ( ) ,'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(8, 27), 'end':(8, 38), 'text':'which , upon association with the ES62 product of filarial nematodes ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 39), 'end':(8, 43), 'text':'traffics into vesicular compartments ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 44), 'end':(8, 53), 'text':'where it sequesters and degrades PKCalpha , a protein kinase'}, {'start':(8, 54), 'end':(8, 63), 'text':'that mediates PLD and SphK activation downstream of FcepsilonRI .'}]}]}]}]}]}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 5), 'text':'A number of cell surface receptors'}, {'start':(9, 6), 'end':(9, 13), 'text':'that contain cytoplasmic immunoreceptor tyrosine based inhibition motifs'}]}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(9, 14), 'end':(9, 32), 'text':'( ITIMs ) are found in mast cells and function to negatively regulate FcepsilonRI activation upon co-engagement with FcepsilonRI'}, {'start':(9, 33), 'end':(9, 39), 'text':'by engaging endogenous negative regulatory pathways .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 1), 'text':'These ITIM'}, {'start':(10, 2), 'end':(10, 3), 'text':'containing receptors'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 4), 'end':(10, 5), 'text':'include FcgammaRIIb'}, {'start':(10, 6), 'end':(10, 16), 'text':'( ) , PIR-B ( ) , gp49B1 ( ) ,'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 17), 'end':(10, 20), 'text':'myeloid associated immunoglobulin receptor'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 21), 'end':(10, 27), 'text':'I ( ) , mast cell function'}, {'start':(10, 28), 'end':(10, 39), 'text':'associated antigen ( ) , signal regulator protein alpha ( ) ,'}]}]}, {'start':(10, 40), 'end':(10, 47), 'text':'and the recently identified Allergin-1 ( ) .'}]}]}]}, {'start':(11, 0), 'end':(11, 13), 'text':'The mechanisms of FcgammaRIIb mediated inhibition of FcepsilonRI activation have been extensively described .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(12, 0), 'end':(12, 5), 'text':'Co-engagement of FcgammaRIIb with FcepsilonRI results'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 6), 'end':(12, 19), 'text':'in Lyn mediated phosphorylation of the tyrosine residue in the FcgammaRIIb ITIM motif ,'}, {'start':(12, 20), 'end':(12, 36), 'text':'which subsequently recruits the protein-tyrosine phosphatase SHIP and the docking protein DOK1 to the FcepsilonRI complex .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(13, 0), 'end':(13, 4), 'text':'SHIP is activated by phosphorylation'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(13, 5), 'end':(13, 10), 'text':'and mediates dephosphorylation of PIP 3'}, {'start':(13, 11), 'end':(13, 15), 'text':'to generate PIP 2 ,'}]}, {'start':(13, 16), 'end':(13, 22), 'text':'thereby directly inhibiting the PI3K pathway .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 7), 'text':'DOK1 recruits and activates Ras GTPase activating protein'}, {'start':(14, 8), 'end':(14, 11), 'text':'( RasGAP ) ,'}]}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(14, 12), 'end':(14, 16), 'text':'which inhibits the Ras pathway'}, {'start':(14, 17), 'end':(14, 25), 'text':'by enhancing the intrinsic GTPase activity of Ras .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 2), 'text':'All other ITIM'}, {'start':(15, 3), 'end':(15, 18), 'text':'containing cell surface receptors inhibit FcepsilonRI activation through the action of SHP-1 and SHP-2 phosphatases .'}]}]}]}]}]}]}]}]}
150	154	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'Summary'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 2), 'text':'A substantial network'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 3), 'end':(1, 8), 'text':'of signaling molecules and adaptor proteins'}, {'start':(1, 9), 'end':(1, 18), 'text':'that function downstream of FcepsilonRI activation has been defined .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 34), 'text':'Future studies will continue to elucidate the cell and membrane biology of FcepsilonRI signaling , novel cell surface and intracellular mediators of FcepsilonRI activation , mechanisms of intracellular calcium signaling , and new inhibitory proteins'}, {'start':(2, 35), 'end':(2, 47), 'text':'that negatively regulate parts of the signaling network downstream of FcepsilonRI activation .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 13), 'text':'Our increasing understanding of FcepsilonRI signaling may lead to the development of new therapeutics'}, {'start':(3, 14), 'end':(3, 23), 'text':'that inhibit FcepsilonRI activation for the treatment of asthma .'}]}]}]}
138	150	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 4), 'text':'Therapeutic Targeting of FcepsilonRI Signaling'}, {'start':(1, 0), 'end':(1, 10), 'text':'Given the clinical efficacy of therapeutic anti-IgE neutralization in asthma ,'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(1, 11), 'end':(1, 14), 'text':'which reduces FcepsilonRI activation'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 15), 'end':(1, 29), 'text':'and has revealed an important role for FcepsilonRI signaling in asthma pathogenesis , future therapies'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 30), 'end':(1, 49), 'text':'that directly target and inhibit FcepsilonRI signaling have significant potential for the treatment of asthma , especially those therapeutic strategies'}, {'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(1, 50), 'end':(1, 63), 'text':'that lead to a more complete and and or faster inhibition of FcepsilonRI activation'}, {'start':(1, 64), 'end':(1, 68), 'text':'compared with anti-IgE therapy .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 2), 'text':'Several intracellular proteins'}, {'start':(2, 3), 'end':(2, 22), 'text':'that play key roles in FcepsilonRI signaling and mast cell activation and whose therapeutic inhibition may lead to superior efficacy'}]}, {'start':(2, 23), 'end':(2, 33), 'text':'compared with anti-IgE therapy have been discussed in this minireview .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 7), 'text':'Of these , there are significant ongoing efforts'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 8), 'end':(3, 17), 'text':'to generate small molecule inhibitors of Syk and PI3K ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 18), 'end':(3, 23), 'text':'which have resulted in some compounds'}, {'start':(3, 24), 'end':(3, 36), 'text':'that have entered human clinical trials for asthma or other allergic diseases .'}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 18), 'text':'There has also been recent progress in the generation of specific small molecule inhibitors of Btk ( ) .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 8), 'text':'The discovery of STIM1 and Orai1 has spurred efforts'}, {'start':(5, 9), 'end':(5, 25), 'text':'to identify novel small molecule inhibitors of these components and regulators of store operated calcium channels .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 2), 'text':'A major concern'}, {'start':(6, 3), 'end':(6, 18), 'text':'associated with many of these small molecule targets is their broad biology beyond FcepsilonRI signaling ,'}]}, {'start':(6, 19), 'end':(6, 29), 'text':'which may result in adverse safety profiles upon therapeutic targeting .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 16), 'text':'An alternative approach to the intracellular small molecule targeting of FcepsilonRI signaling utilizes protein based therapeutics ,'}, {'start':(7, 17), 'end':(7, 27), 'text':'which are well suited for specifically targeting cell surface proteins .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 6), 'text':'Several groups have developed protein based therapeutics'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(8, 7), 'end':(8, 11), 'text':'that directly inhibit FcepsilonRI activation'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 12), 'end':(8, 19), 'text':'by co-cross-linking FcepsilonRI with various cell surface ITIM'}, {'start':(8, 20), 'end':(8, 26), 'text':'containing receptors , most commonly FcgammaRIIb .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 8), 'text':'These approaches include an IgE-Fc and IgG-Fc fusion protein'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 9), 'end':(9, 24), 'text':'that simultaneously engages FcepsilonRI and FcgammaRIIb ( ) , a specific allergen and IgG-Fc fusion protein'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 25), 'end':(9, 30), 'text':'that simultaneously engages allergen specific IgE'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 31), 'end':(9, 45), 'text':'that is bound to FcepsilonRI and FcgammaRIIb ( ) , and various bispecific antibody technologies'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 46), 'end':(9, 53), 'text':'that co-cross-link FcepsilonRI with FcgammaRIIb or other ITIM'}, {'start':(9, 54), 'end':(9, 56), 'text':'containing receptors .'}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 5), 'text':'Limitations of several of these protein'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 6), 'end':(10, 17), 'text':'based therapeutics include poor in vivo pharmacokinetics , immunogenicity , and difficulties'}, {'start':(10, 18), 'end':(10, 22), 'text':'associated with large-scale manufacturing ,'}]}]}, {'start':(10, 23), 'end':(10, 35), 'text':'although some new bispecific antibody formats can overcome many of these limitations .'}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'start':(11, 0), 'end':(11, 14), 'text':'Given the increasing development and use of antibody therapeutics for the treatment of diseases ,'}, {'start':(11, 15), 'end':(11, 33), 'text':'including asthma , novel bispecific antibody approaches may help expand the scope of therapeutic targets in the future .'}]}]}]}
46	72	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 4), 'text':'Signaling Events Proximal to FcepsilonRI'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 6), 'text':'Intracellular FcepsilonRI signaling proceeds through a network'}, {'start':(1, 7), 'end':(1, 15), 'text':'of signaling molecules and adaptor proteins ( ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 7), 'text':'The Src family kinases mediate intracellular signaling events'}, {'start':(2, 8), 'end':(2, 13), 'text':'that are proximal to FcepsilonRI .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(3, 0), 'end':(3, 12), 'text':'Lyn is the most highly expressed Src family kinase in mast cells ,'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(3, 13), 'end':(3, 17), 'text':'and it initiates FcepsilonRI signaling'}, {'start':(3, 18), 'end':(3, 26), 'text':'by phosphorylating the ITAMs of FcRbeta and FcRgamma .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 22), 'text':'However , the overall role of Lyn as a positive or negative regulator of mast cell activation downstream of FcepsilonRI is controversial .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 30), 'text':'Substrates for Lyn phosphorylation include both positive regulators of FcepsilonRI signal transduction such as Syk and negative regulators of FcepsilonRI signal transduction such as Cbp ( Csk binding protein ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 31), 'end':(5, 41), 'text':'which recruits Csk , a negative regulator of Src family kinases'}, {'start':(5, 42), 'end':(5, 45), 'text':'( - ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 11), 'text':'In vitro studies of Lyn knock-out mast cells have demonstrated increased ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(6, 12), 'end':(6, 16), 'text':'decreased , or unaffected degranulation'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 17), 'end':(6, 23), 'text':'and increased cytokine production upon FcepsilonRI activation'}, {'start':(6, 24), 'end':(6, 34), 'text':'compared with wild-type mast cells ( , , - ) .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 25), 'text':'The discrepancy in effects of Lyn deficiency on mast cell degranulation in these various studies may be due to genetic differences in Fyn expression and activity'}, {'start':(7, 26), 'end':(7, 36), 'text':'that are associated with different mouse background strains ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 12), 'text':'It may also be due to differences in the strength of FcepsilonRI stimulation'}, {'start':(8, 13), 'end':(8, 34), 'text':'that result in differences in the net role of Lyn as a positive or negative regulator of FcepsilonRI signaling ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 31), 'text':'The interpretation of in vivo studies of Lyn knock-out mice is complicated by age dependent increases in serum IgE , total numbers of mast cells , and spontaneous mast cell activation .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 10), 'text':'Young Lyn knock-out mice have a hyper-responsive degranulation phenotype in vivo'}, {'start':(10, 11), 'end':(10, 15), 'text':'compared with wild-type mice ,'}]}, {'start':(10, 16), 'end':(10, 36), 'text':'indicating an overall negative regulatory role for Lyn in mast cell degranulation downstream of FcepsilonRI activation in vivo ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(11, 0), 'end':(11, 12), 'text':'Although older Lyn knock-out mice have a defective degranulation phenotype in vivo ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 13), 'end':(11, 21), 'text':'this phenotype appears to result from a reduced ability'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 22), 'end':(11, 43), 'text':'to sensitize these mice with exogenous IgE due to high circulating levels of endogenous IgE as opposed to inherent defects in FcepsilonRI'}, {'start':(11, 44), 'end':(11, 48), 'text':'mediated mast cell activation .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 0), 'end':(12, 3), 'text':'Other Src family kinases'}, {'start':(12, 4), 'end':(12, 15), 'text':'that play a role in FcepsilonRI signaling are Fyn and Hck .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 28), 'text':'Both Fyn and Hck have positive regulatory roles in mast cell activation such that Fyn and Hck knock-out mast cells have reduced degranulation and cytokine production upon FcepsilonRI activation'}, {'start':(13, 29), 'end':(13, 32), 'text':'( - ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 9), 'text':'Fyn is involved in the activation of lipid signaling pathways'}, {'start':(14, 10), 'end':(14, 22), 'text':'mediated by PI3K , sphingosine kinase ( SphK ) , and phospholipase D'}]}, {'start':(14, 23), 'end':(14, 26), 'text':'( PLD ) ,'}]}, {'start':(14, 27), 'end':(14, 32), 'text':'which are discussed further below .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 7), 'text':'Among Lyn , Fyn , and Hck ,'}, {'start':(15, 8), 'end':(15, 12), 'text':'Hck negatively regulates Lyn ,'}]}, {'start':(15, 13), 'end':(15, 20), 'text':'and Lyn negatively regulates Fyn ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 0), 'end':(16, 15), 'text':'Lyn knock-out mast cells with enhanced Fyn activity are hyper-responsive to FcepsilonRI activation ( ) .'}, {'start':(17, 0), 'end':(17, 21), 'text':'Reduction of Lyn function through disruption of Lyn localization to lipid rafts can also lead to increased Fyn activity ( ) .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 0), 'end':(18, 8), 'text':'This may provide an explanation for the allergic phenotypes'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 9), 'end':(18, 19), 'text':'that are observed in humans with Smith-Lemli-Opitz syndrome , a disease'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 20), 'end':(18, 37), 'text':'that arises from a defective gene mutant of 3beta-hydroxysterol Delta 7 -reductase ( DHCR7 ) , an enzyme'}, {'start':(18, 38), 'end':(18, 43), 'text':'that converts 7-dehydrocholesterol to cholesterol .'}]}]}]}, {'start':(19, 0), 'end':(19, 32), 'text':'Knock-out of DHCR7 in mice results in a disruption of lipid raft stability due to low cholesterol levels and a reduction in the lipid raft localization of FcepsilonRI and Lyn ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 10), 'text':'Fyn activity is increased in DHCR7 knock-out mouse mast cells ,'}, {'start':(20, 11), 'end':(20, 21), 'text':'resulting in increased mast cell degranulation upon activation of FcepsilonRI .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 9), 'text':'A key mediator of proximal FcepsilonRI signaling is Syk ,'}, {'start':(21, 10), 'end':(21, 24), 'text':'which is recruited to the FcepsilonRI complex by association with phosphorylated FcRgamma ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(22, 0), 'end':(22, 6), 'text':'Subsequent to its association with FcepsilonRI ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(22, 7), 'end':(22, 9), 'text':'Syk is phosphorylated'}, {'start':(22, 10), 'end':(22, 14), 'text':'and activated by Lyn .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 0), 'end':(23, 8), 'text':'Syk phosphorylates the adaptor proteins LAT and NTAL/LAB/LAT2 ,'}, {'start':(23, 9), 'end':(23, 14), 'text':'whose functions are described below ,'}]}, {'start':(23, 15), 'end':(23, 25), 'text':'and thereby coordinates the activation of multiple downstream signaling pathways .'}]}, {'start':(24, 0), 'end':(24, 16), 'text':'This ultimately leads to mast cell degranulation , eicosanoid production , and cytokine production ( ) .'}]}, {'start':(25, 0), 'end':(25, 15), 'text':'Structural and functional aspects of Syk activity in mast cell signaling have been reviewed extensively .'}]}]}]}]}]}]}
27	46	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 10), 'text':'FcepsilonRI Expression , Distribution , and Dynamics at the Cell Surface'}, {'start':(1, 0), 'end':(1, 22), 'text':'The FcepsilonRIalpha , FcRbeta , and FcRgamma components of the tetrameric FcepsilonRI complex in mast cells have different functions in FcepsilonRI signaling .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 4), 'text':'FcepsilonRIalpha contains an extracellular domain'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 5), 'end':(2, 7), 'text':'that binds IgE'}, {'start':(2, 8), 'end':(2, 15), 'text':'but does not directly mediate intracellular signaling .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 11), 'text':'FcRgamma contains a cytoplasmic immunoreceptor tyrosine based activation motif ( ITAM )'}, {'start':(3, 12), 'end':(3, 23), 'text':'that couples FcepsilonRI cross linking to the initiation of intracellular signaling .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(4, 0), 'end':(4, 4), 'text':'FcRbeta also contains an ITAM'}, {'start':(4, 5), 'end':(4, 13), 'text':'and functions as an amplifier of intracellular signals .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 16), 'text':'The cell surface expression of the human FcepsilonRI complex is regulated by a number of factors .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 9), 'text':'FcepsilonRIalpha contains multiple endoplasmic reticulum ( ER ) retention signals'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 10), 'end':(6, 25), 'text':'that reside in the signal peptide , transmembrane , and cytoplasmic regions of the FcepsilonRIalpha sequence'}, {'start':(6, 26), 'end':(6, 29), 'text':'( - ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 11), 'text':'Additional residues in the transmembrane domain of FcepsilonRIalpha mediate interactions with FcRgamma'}, {'start':(7, 12), 'end':(7, 21), 'text':'that are required for cell surface expression ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 19), 'text':'In addition to its role in directly promoting FcepsilonRI signaling via its ITAM , FcRbeta also acts as a chaperone'}, {'start':(8, 20), 'end':(8, 28), 'text':'that increases cell surface FcepsilonRI expression ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 40), 'text':'Members of the Rab family of GTPases and their intracellular cofactors , such as Rab5 , Rabex-5 / RabGEF1 , and Rabaptin-5 , regulate cell surface levels of FcepsilonRI by modulating FcepsilonRI internalization and the cell surface stability of FcepsilonRI .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(10, 0), 'end':(10, 22), 'text':'Cross linking of many cell surface receptors results in receptor partitioning to detergent-insoluble membrane lipid fractions ( lipid rafts ) ( ) .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 8), 'text':'Lipid rafts are enriched in signaling and adaptor molecules'}, {'start':(11, 9), 'end':(11, 14), 'text':'that mediate intracellular signal transduction ,'}]}, {'start':(11, 15), 'end':(11, 30), 'text':'and the localization of cell surface receptors to lipid rafts assists the signal transduction process .'}]}]}]}]}]}]}]}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(12, 0), 'end':(12, 8), 'text':'For FcepsilonRI , biochemical and biophysical studies have demonstrated'}, {'label':'joint', 'direction':'None', 'children':[{'start':(12, 9), 'end':(12, 11), 'text':'that cross linking'}, {'label':'joint', 'direction':'None', 'children':[{'start':(12, 12), 'end':(12, 23), 'text':'and activation are associated with redistribution of FcepsilonRI to lipid rafts ,'}, {'start':(12, 24), 'end':(12, 39), 'text':'and this recruitment of FcepsilonRI to lipid rafts is important for FcepsilonRI signaling ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 18), 'text':'However , the overall role of lipid rafts in the initiation versus maintenance of FcepsilonRI signaling is unclear .'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(14, 0), 'end':(14, 5), 'text':'One model of FcepsilonRI signaling postulates'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 6), 'end':(14, 13), 'text':'that activation is initiated in lipid rafts ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 14), 'end':(14, 22), 'text':'requiring the recruitment of FcepsilonRI to lipid raft environments'}, {'start':(14, 23), 'end':(14, 33), 'text':'that contain the initiating Src family kinase Lyn ( ) .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(15, 0), 'end':(15, 5), 'text':'Another model of FcepsilonRI signaling postulates'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 6), 'end':(15, 16), 'text':'that activation can be initiated outside of lipid raft compartments ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 17), 'end':(15, 22), 'text':'where a small fraction of Lyn'}, {'start':(15, 23), 'end':(15, 37), 'text':'that is pre-associated with the FcR beta-subunit activates FcepsilonRI signaling upon receptor cross linking .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(16, 0), 'end':(16, 28), 'text':'In this model , the recruitment of FcepsilonRI to lipid rafts is important for signal propagation and maintenance through adaptor proteins such as LAT , but not initiation .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(17, 0), 'end':(17, 26), 'text':'Recent biophysical studies of FcepsilonRI and membrane lipid distribution and dynamics have enabled the monitoring of very small lipid raft microdomains in cells under physiologic conditions .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(18, 0), 'end':(18, 10), 'text':'The results of these studies suggest a hybrid of both models'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(18, 11), 'end':(18, 12), 'text':'and indicate'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 13), 'end':(18, 19), 'text':'that lipid raft microdomains coalesce upon cross'}, {'label':'joint', 'direction':'None', 'children':[{'start':(18, 20), 'end':(18, 22), 'text':'linking of FcepsilonRI'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 23), 'end':(18, 32), 'text':'and redistribute with aggregated FcepsilonRI proteins in a time frame'}, {'start':(18, 33), 'end':(18, 41), 'text':'that correlates with the kinetics of FcepsilonRI phosphorylation .'}]}]}]}]}]}]}]}]}]}]}
82	109	{'label':'explanation', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 4), 'text':'Lipid Signaling Downstream of FcepsilonRI'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 11), 'text':'Several lipid signaling pathways are activated downstream of FcepsilonRI via Fyn ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 12), 'end':(1, 13), 'text':'including pathways'}, {'start':(1, 14), 'end':(1, 22), 'text':'mediated by PI3K , SphK , and PLD .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 11), 'text':'The PI3K enzymes catalyze the phosphorylation of the inositol ring of membrane'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 12), 'end':(2, 14), 'text':'associated phosphatidylinositol 4,5-bisphosphate'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 15), 'end':(2, 22), 'text':'( PIP 2 ) at the D3 position'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 23), 'end':(2, 26), 'text':'to generate phosphatidylinositol 1,4,5-triphosphate'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 27), 'end':(2, 36), 'text':'( PIP 3 ) , a major intracellular lipid mediator'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 37), 'end':(2, 43), 'text':'that has effects on multiple signaling pathways'}, {'start':(2, 44), 'end':(2, 50), 'text':'involved in degranulation and cytokine production .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 8), 'text':'The PI3K enzyme family consists of three subclasses ,'}, {'start':(3, 9), 'end':(3, 20), 'text':'of which the class I PI3Ks are the most well understood .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 5), 'text':'The class I PI3Ks are further'}, {'start':(4, 6), 'end':(4, 14), 'text':'subdivided into class IA and class IB PI3Ks .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(5, 0), 'end':(5, 15), 'text':'The class IA PI3Ks consist of a p85 regulatory subunit and a p110 catalytic subunit ;'}, {'start':(5, 16), 'end':(5, 27), 'text':'there are five isoforms of p85 and three isoforms of p110 .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 18), 'text':'The class IB PI3Ks consist of a p101 or p87 PIKAP regulatory subunit and a p110 catalytic gamma-subunit .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(7, 0), 'end':(7, 8), 'text':'The p110 alpha- and beta-isoforms are ubiquitously expressed ,'}, {'start':(7, 9), 'end':(7, 27), 'text':'and the p110 delta- and gamma-isoforms ( p110delta and p110gamma , respectively ) are expressed mainly in leukocytes .'}]}, {'start':(8, 0), 'end':(8, 14), 'text':'Both p110delta and p110gamma contribute to FcepsilonRI signaling in mast cells ( - ) .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(9, 0), 'end':(9, 7), 'text':'p110delta is directly activated downstream of FcepsilonRI ,'}, {'start':(9, 8), 'end':(9, 34), 'text':'and genetic and pharmacologic inactivation of p110delta leads to reduced mast cell degranulation , eicosanoid production , and cytokine production both in vitro and in vivo .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 13), 'text':'The role of p110gamma in FcepsilonRI induced mast cell activation is more controversial .'}, {'start':(11, 0), 'end':(11, 6), 'text':'p110gamma is activated by G-protein-coupled receptors .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 0), 'end':(12, 14), 'text':'As such , it is indirectly activated downstream of FcepsilonRI via autocrine mast cell signals'}, {'start':(12, 15), 'end':(12, 27), 'text':'that are mediated by adenosine and other G-protein-coupled receptor agonists ( ) .'}]}]}]}]}, {'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 13), 'text':'In vitro stimulation of mast cells from p110gamma knock-out mice results in reduced degranulation'}, {'start':(13, 14), 'end':(13, 21), 'text':'compared with mast cells from wild-type mice .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 1), 'text':'However ,'}, {'start':(14, 2), 'end':(14, 43), 'text':'whereas one study reported reduced in vivo activation of mast cells in p110gamma knock-out mice ( ) , another study reported a lack of effect of p110gamma knock-out or pharmacologic inactivation of p110gamma on in vivo mast cell activation ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'cause', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 1), 'text':'PIP 3'}, {'start':(15, 2), 'end':(15, 25), 'text':'that is generated by PI3K enzymes recruits several signaling proteins to the cell membrane via interaction with pleckstrin homology domains in these proteins ,'}]}, {'start':(15, 26), 'end':(15, 30), 'text':'thereby propagating intracellular signaling .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 0), 'end':(16, 5), 'text':'These signaling effectors include PDK1 ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 6), 'end':(16, 8), 'text':'which activates Akt'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 9), 'end':(16, 20), 'text':'to promote cell proliferation and survival ( ) , and Btk ,'}, {'start':(16, 21), 'end':(16, 24), 'text':'which activates PLCgamma .'}]}]}]}]}, {'start':(17, 0), 'end':(17, 10), 'text':'PIP 3 also has regulatory effects on PLD and SphK .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 0), 'end':(18, 16), 'text':'PI3K is positively regulated by RasGRP1 ( ) , in addition to being activated by Fyn .'}, {'label':'explanation', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 0), 'end':(19, 15), 'text':'Mast cells from RasGRP1 knock-out mice show defects in multiple pathways downstream of PIP 3 ,'}, {'start':(19, 16), 'end':(19, 21), 'text':'including reduced phosphorylation of Akt .'}]}, {'start':(20, 0), 'end':(20, 16), 'text':'This results in reduced degranulation and cytokine production upon FcepsilonRI activation of RasGRP1 knock-out mast cells .'}]}]}]}]}, {'start':(21, 0), 'end':(21, 9), 'text':'SphKs generate sphingosine 1-phosphate ( S1P ) from sphingosine .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'None', 'children':[{'start':(22, 0), 'end':(22, 5), 'text':'There are two SphK isoforms ,'}, {'start':(22, 6), 'end':(22, 22), 'text':'but the contribution of each SphK isoform to FcepsilonRI signaling and mast cell activation is controversial .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 0), 'end':(23, 6), 'text':'One group has defined an intracellular pathway'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 7), 'end':(23, 11), 'text':'whereby SphK2 generates S1P ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 12), 'end':(23, 17), 'text':'which subsequently promotes intracellular calcium signaling'}, {'start':(23, 18), 'end':(23, 29), 'text':'that results in mast cell degranulation and cytokine production ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 0), 'end':(24, 6), 'text':'SphK1 in other cell types generates S1P'}, {'label':'joint', 'direction':'None', 'children':[{'start':(24, 7), 'end':(24, 10), 'text':'that is released extracellularly'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(24, 11), 'end':(24, 21), 'text':'and acts on mast cells via the S1P1 and S1P2 receptors'}, {'start':(24, 22), 'end':(24, 39), 'text':'to promote mast cell migration and to enhance mast cell degranulation and cytokine production upon FcepsilonRI activation .'}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(25, 0), 'end':(25, 9), 'text':'On the other hand , data from other groups indicate'}, {'start':(25, 10), 'end':(25, 12), 'text':'that SphK1 ,'}]}, {'start':(25, 13), 'end':(25, 17), 'text':'as opposed to SphK2 ,'}]}, {'start':(25, 18), 'end':(25, 32), 'text':'is the major intracellular source of S1P in mast cells downstream of FcepsilonRI activation .'}]}, {'start':(26, 0), 'end':(26, 22), 'text':'These groups have also described roles for extracellular S1P in mast cell migration and FcepsilonRI activation via the S1P1 and S1P2 receptors .'}]}]}
